Antimicrobial resistance (AMR) is one of the greatest health challenges of our time.

It threatens us all, however the most vulnerable are at the most risk.

If we don't prioritise action now, we will see a steady increase in the global death toll.

Yesterday, we shared Wellcome's recommendations for driving more ambitious action on AMR – echoing The Lancet's call for target-based approaches and improved accountability.
You can find out more in our policy brief.
wellcome.org/reports/drivin…

“The problem of [antimicrobial resistance (AMR)] has been seen as either not urgent or too difficult to solve. Neither is true.”

🆕 A Lancet Series spotlights this global issue & how existing infection prevention methods could save 750,000 lives a year: hubs.li/Q02ylby30

🆕️⚡️⚡️ #ACC
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection #idxposts
journals.asm.org/doi/10.1128/aa…

This is a very important report! It shows that plans for access to promising new antimicrobials by LMICs with large populations affected by AMR are largely lacking. It is essential that progress on this is tracked and that words turn into action.

NOW ONLINE: Our new report analyses the five most promising projects currently in the antimicrobial pipeline that could save 160,000 lives yearly by treating drug-resistant infections. Read more➡️accesstomedicinefoundation.org/news/more-supe… #AMR Foreign, Commonwealth & Development Office Ministerie van VWS Wellcome AXA IM Stewart Investors

AMR is a global health crisis that will affect us all.

Political events this year present a unique opportunity for the world to unite in more effective, collective action.

We're calling for an approach informed by scientific evidence, clear targets and accountability.

Congratulations DrTrishaPeel and the ASAP Trial team!!

This is a make deal - the Australian peak body and award for clinical trials. ACTA: Australian Clinical Trials Alliance

Well deserved. Doing clinical trials that make a difference!

nejm.org/doi/full/10.10…

Congratulations all ACTA: Australian Clinical Trials Alliance #TrialOfTheYearAward recipients and nominees.

Special congratulations to Trial
Of The Year winner DrTrishaPeel and the ASAP Trial based at Translational Medicine at Monash University!

Practice changing infectious diseases research ASIDANZ The Alfred
nejm.org/doi/full/10.10…

Likely excellent infection control. No shortage of CRAB elsewhere in Asia, unfortunately...

Great to see Sulbactam-Durlobactam getting to China! Now, let's see availability elsewhere in the world!!
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® for Acinetobacter HAP and VAP in China.
businesswire.com/news/home/2024…

Thank you to the Guardian for your opinion piece highlighting AMR as a global health threat. You are spot on. #AMR theguardian.com/commentisfree/…

New WHO Bacterial Priority Pathogens List - critical group now down to 3 - CR-Acinetobacter, CRE and 3GC resistant Enterobacterales (Pseudomonas now in 'high' group)

Prince William The Prince and Princess of Wales delivers a powerful call to action to #StopSuperbugs .

“With the right type of policies, we can incentivize #innovation to address #AMR .”

#AMR SOS #antibioticemergency

GSK, UK government budget £130M to fight global antimicrobial resistance - endpts.com/gsk-uk-governm…

At the 'World Together Solving the Antibiotic Emergency' meeting, UK (Jeremy Hunt) + KSA (Abdulaziz Al-Rumaih) announced joint funding of ~£20m of an Independent Panel on Evidence on AMR as called for by GLG AMR! See amr.solutions/2024/04/19/amr…. Fabulous! #FireExtingushersOfMedicine

Thanks Access to Medicine Foundation FAIRR Initiative Department of Health and Social Care for highlighting the urgency of funding the development of new #antimicrobials , and planning for #access2meds early in the R&D process, in your Investor Action on AMR Public Investor Statement!

#AMR #StopSuperbugs

amrinvestoraction.org/article/invest…

On right now!!!

An international partnership between #ARLGnetwork , Ecraid, and ADVANCE-ID Network has been forged to combat #AntibacterialResistance on a global scale! Read more about this incredible alliance here: bit.ly/3UgHSUM. #ClinicalResearch #PublicHealth

In vitro antibacterial activity of sulbactam-durlobactam in combinatio... sciencedirect.com/science/articl…